About Zavante
Zavante is a company based in San Diego (United States) founded in 2015 was acquired by Nabriva in July 2018. Zavante has raised $80.01 million across 5 funding rounds from investors including Nabriva, Frazier Healthcare Partners and Longitude Capital. Zavante offers products and services including ZOLYD and Clinical Trials Services. Zavante operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zavante Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zavante
Zavante offers a comprehensive portfolio of products and services, including ZOLYD and Clinical Trials Services.
Investigational injectable for treating multi-drug resistant bacterial infections
Conducts trials for new antibiotics targeting serious hospital infections
Funding Insights of Zavante
Zavante has successfully raised a total of $80.01M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $10 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zavante
Zavante has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Nabriva, Frazier Healthcare Partners and Longitude Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked |
Investor details for Zavante
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zavante
Investment portfolio details for Zavante
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Zavante
Detailed financials for Zavante
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zavante Comparisons
Peer comparison for Zavante
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zavante
Zavante operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| Locked | Locked | Locked |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
Detailed competitors of Zavante
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zavante
Complete news archive for Zavante
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zavante
Zavante was founded in 2015.
Zavante is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Zavante is a funded company, having raised a total of $80.01M across 5 funding rounds to date.
Zavante is a US-based, late clinical stage biotech developing IV Fosfomycin for cUTI and other MDR infections. Its lead product candidate, ZTI-01, ZOLYD, is a first-in-class injectable antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains where current therapeutic choices are severely limited. ZTI-01ZOLYD, or IV Fosfomycin, is bactericidal and inhibits bacterial cell wall biogenesis by inactivating the enzyme UDP-N-acetylglucosamine-3-enol-pyruvyl transferase, also known as MurA. As on Aug.2017, ZOLYD is in Phase III trials for the treatment of cUTI, including acute pyelonephritis. The other indications for cUTI are cIAI, ABSSSI, HABPVABP, and others.
Zavante's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Zavante offers ZOLYD and Clinical Trials Services.
Zavante has 4 investors. Key investors include Nabriva, Frazier Healthcare Partners, Longitude Capital, and Aisling Capital.